期刊文献+

阿托伐他汀钙片在中国健康受试者的生物等效性试验 被引量:1

Bioequivalence study of atorvastatin calcium tablets in Chinese healthy volunteers
下载PDF
导出
摘要 目的:研究阿托伐他汀钙片与原研制剂立普妥的人体生物等效性。方法:64例健康受试者参加空腹试验,64例健康受试者参加餐后试验,均采用两周期双交叉试验设计,先后口服受试制剂或参比制剂10 mg,采用液相色谱-串联质谱法测定人血浆中阿托伐他汀及其两种活性代谢物的浓度。使用WinNonlin 7.0软件进行数据处理。结果:空腹给药后阿托伐他汀钙片受试制剂与参比制剂的C_(max)分别为(4.31±2.24)、(4.64±2.73) ng/mL,T_(max)分别为(0.58±0.36)、(0.58±0.35) h,t_(1/2)分别为(9.10±2.67)、(9. 16±3. 13)h,AUC_(0-t)分别为(23.79±10.73)、(21.93±9.29)ng·h·mL^(-1),AUC_(0-∞)分别为(24. 87±10. 88)、(23.04±9.29) ng·h·mL^(-1)。餐后给药后阿托伐他汀钙片受试制剂与参比制剂的C_(max)分别为(2.41±1.37)、(2.39±1.21) ng/mL,T_(max)分别为(2.38±1.43)、(2.15±1.54) h,t_(1/2)分别为(10.86±8.77)、(9.59±2.81) h,AUC_(0-t)分别为(19.03±9.26)、(19.25±9.20) ng·h·mL^(-1),AUC_(0-∞)分别为(20.25±9.30)、(20.39±9.27)ng·h·mL^(-1)。结论:阿托伐他汀钙片受试制剂与参比制剂在空腹和餐后条件下均生物等效。 AIM: To study human bioequivalence between atorvastatin tablets and original preparation Lipitor. METHODS: Sixty-four healthy subjects participated in the fasting test and 64 healthy subjects participated in the postprandial test. Both were designed using a randomized two-way crossover study. They were orally administered with 10 mg of the test preparation or reference preparation. The plasma concentration of atorvastatin and its two active metaboliteswere determined by LC-MS/MS. By means of WinNonlin 7.0 software, pharmacokinetic parameters were calculated.RESULTS:The pharmacokinetic parameters for atorvastatin of the two preparations under fasting condition were as follow: C max of test and reference preparations were (4.31±2.24), (4.64±2.73)ng/mL, T max were (0.58±0.36), (0.58±0.35) h,t 1/2 were (9.10±2.67), (9.16±3.13) h,AUC 0-t were (23.79±10.73),(21.93±9.29) ng·h·mL^-1,AUC 0-∞ were (24.87±10.88), (23.04±9.29) ng·h·mL ^-1. The pharmacokinetic parameters for atorvastatin of the two preparations under fed condition were as follow: C max of test and reference preparations were(2.41±1.37),(2.39±1.21) ng/mL,Tmax were (2.38±1.43),(2.15±1.54) h,t 1/2 were (10.86±8.77),(9.59±2.81) h,AUC0-t were (19.03±9.26), (19.25±9.20) ng·h·mL ^-1,AUC 0-∞ were (20.25±9.30), (20.39±9.27) ng·h·mL ^-1. CONCLUSION: The atorvastatin calcium test formulation and the reference formulation were both bioequivalent in both fasting and postprandial conditions.
作者 杨亚楠 陈莉梅 陶春蕾 YANG Yanan;CHEN Limei;TAO Chunlei(Graduate School ,Anhui University of Chinese Medicine ,Hefei230012,Anhui,China)
出处 《中国临床药理学与治疗学》 CAS CSCD 2018年第11期1258-1264,共7页 Chinese Journal of Clinical Pharmacology and Therapeutics
关键词 阿托伐他汀 邻羟基阿托伐他汀 对羟基阿托伐他汀 生物等效性 atorvastatin ortho-hydroxy atorvastatin para-hydroxy atorvastatin bioequivalence
  • 相关文献

参考文献4

二级参考文献45

  • 1邸晓辉,杨永革,梅巍,刘静,许雪廷.阿托伐他汀钙胶囊的人体生物等效性研究[J].解放军药学学报,2005,21(4):262-265. 被引量:8
  • 2Steven E. Nissen,Stephen J. Nicholls,Ilks Sipahi,Peter Libby,Joel S. Raichlen,Christie M. Ballantyne,Jean Davignon,Raimund Erbel,Jean Charles Fruchart,Jean-Claude Tardif,Paul Schoenhagen,Tim Crowe,Valerie Cain,Kathy Wolski,Marlene Coormastic,E. Murat Tuzcu,仝其广(译),王淑敏(译),胡大一(校).极高强度他汀治疗对冠状动脉粥样硬化消退的影响——ASTEROID试验[J].美国医学会杂志(中文版),2006,25(4):215-223. 被引量:345
  • 3国家药典委员会《.中国药典》(二部)附录V D,HPLC法测定[M].北京:化学工业出版社,2005. 被引量:1
  • 4SHIN J, PAULY DF, PACANOWSKI MA, et al. Effect of cytochrome 17450 3A5 genotype on atorvastatin pharmacokinetics and its interaction with clarithromycin[J]. Pharmacotherapy, 2011, 31(10) : 942-950. 被引量:1
  • 5FURMAN A, MEIER JL, MALMSTROM RA, et al. Comparative efficacy of ezetimibe/simvastatin, rosuvastatin, and atorvastatin in uncontrolled hyperlipidemia patients [J]. Am J Manag Care,2011, 17(8): 538-544. 被引量:1
  • 6BULLEN WW, MILLER RA, HAYES RN. Development and validation of a high-performance liquid chromatography tandem mass spectrometry assay for atorvastatin, ortho- hydroxy atorvastatin, and para-hydroxy atorvastatin in human, dog, and rat plasma[J]. J Am Soc Mass spectrom, 1999, 10(1 ): 55-66. 被引量:1
  • 7JOCOBSEN W, KUHN B, SOLDNER A, et al. Lactonization is the critical first step in the disposition of the 3- hydroxy- 3- methylglutaryl- CoA reductase inhibotor atorvastatin [J]. Drug Metab Dispos, 2000, 28 ( 11 ) : 1369-1378. 被引量:1
  • 8LIU YM, PU HH, LIU GY, et al. Pharmacokinetics and bioequivalence evaluation of two different atorvastatin calcium 10 - mg tablets: A single - dose, randomized - sequence, open - label, two-period crossover study in healthy fasted Chinese adult males[J]. Clin Ther, 2010, 32(7): 1396-1407. 被引量:1
  • 9LENNERNAS H. Clinical pharmacokineties of atorvastatin [J]. Clin Pharmacokinet, 2003, 42(13): 1141-1160. 被引量:1
  • 10RAMAKRISHNA NV, KOTESHWARA M, VISHWOTTAM KN, et al. Simple, sensitive and rapid LC- MS- MS method for the quantitation of cerivastatin in human plasma- application to pharmacokinetic studies[J]. J Pharma Biomed Anal, 2004, 36 (3): 505-515. 被引量:1

共引文献43

同被引文献1

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部